CONMED Corp. 10-Q Summary: Quarter Ended June 28, 1996
Business Context and Reporting Period
CONMED Corporation, a developer, manufacturer, and marketer of disposable medical products and related devices, filed its Form 10-Q for the quarter and six months ended June 28, 1996. The company is based in Utica, New York. As of July 20, 1996, there were 14,937,676 shares of common stock outstanding.
Key Financial Metrics
| Metric | 3 Months Ended June 28, 1996 | 6 Months Ended June 28, 1996 |
|---|---|---|
| Net Sales | $31,790,000 | $60,990,000 |
| Net Income | $4,224,000 | $7,496,000 |
| Earnings Per Share (EPS) | $0.28 | $0.54 |
| Gross Margin | 48.1% | 48.1% |
| Operating Income | $6,451,000 | $12,245,000 |
| Cash from Operations | N/A | $7,090,000 |
| Total Debt | $0 | $0 |
| Cash and Equivalents | $8,348,000 | $8,348,000 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 22.9% for the quarter and 34% for the six-month period compared to 1995. This growth is primarily attributed to the acquisitions of New Dimensions in Medicine (NDM), Master Medical, and Birtcher Medical Systems.
- Profitability: Net income rose 50% for the quarter and 61% for the six-month period. Gross margin improved to 48.1% from 47.8% (quarter) and 46.9% (six months) due to economies of scale and manufacturing efficiencies.
- Debt Elimination: The company repaid all outstanding indebtedness ($65 million) in March 1996 using proceeds from a public equity offering. Consequently, interest expense turned into interest income for the quarter, and total debt on the balance sheet is zero.
- Balance Sheet: Total assets increased from $119.4 million to $162.5 million, driven by goodwill from acquisitions and increased cash reserves. Goodwill rose from $41.4 million to $61.4 million.
Guidance, Outlook, and Risks
Management Commentary: Management attributes improved margins to economies of scale and the relocation of the ECG electrode manufacturing facility from Massachusetts to New York. Selling and administrative expenses as a percentage of sales declined due to the elimination of duplicate costs from acquired businesses.
Liquidity: The company maintains a $60 million secured revolving credit facility expiring in March 2001. Management believes current cash resources and operating cash flows are sufficient for working capital and capital expenditures.
Risks and Contingencies:
- Acquisition Integration: The allocation of the purchase price for the NDM acquisition is based on preliminary estimates and may be re-allocated within the next twelve months, though management does not expect a material effect.
- Seasonality: Results for the interim periods are not necessarily indicative of results for the full year.
Investor Verification Checklist
- Verify the final allocation of the purchase price for the New Dimensions in Medicine (NDM) acquisition and any potential adjustments to goodwill.
- Confirm the sustainability of the 48.1% gross margin as the company integrates acquired operations.
- Review the terms and covenants of the $60 million revolving credit facility to ensure no restrictions on future operations.
- Monitor the impact of the stock split (3-for-2) and the March 1996 equity offering on future dilution and share count.